Ovarian Cancer Victims Ask Court to Block Johnson & Johnson's 'Texas Two-Step' Bankruptcy Plan

Attorneys for thousands of women diagnosed with ovarian cancer after decades of exposure to Johnson & Johnson's (NYSE:JNJ) talcum powder products are seeking a temporary restraining order and permanent injunction to prevent J&J, or any of its corporate affiliates, from transferring assets to a subsidiary and plunging it into bankruptcy.

The company has not denied that it is scheming to shield its $500 billion in assets from women cancer victims by moving its growing talc-cancer liabilities to a subsidiary before forcing that entity into bankruptcy. The total damages suffered by current talc-cancer victims is estimated at close to $17 billion .  Historically, bankruptcy cases filed to resolve litigation, including those related to asbestos, often take years, and almost never fully repay creditors, including personal injury victims.

In a motion filed in state district court in Missouri , the women argue that such a move amounts to a fraudulent conveyance and that laws in Missouri and most other states prevent such transfers of liabilities by solvent and profitable companies.  They also note that such an approach could immediately halt more than 34,000 claims by ovarian cancer victims and force all related litigation into bankruptcy court, rather than giving these victims their day in trial court before judges and juries.

"Johnson & Johnson has actively threatened attorneys for plaintiffs with this scheme to force out-of-court settlements at pennies on the dollar. This is clear from what has been widely reported, combined with J&J's response," says Andy Birchfield , Mass Tort Section Head of the Beasley Allen law firm , attorney for three women or surviving relatives named in the filing. "J&J has betrayed its customers and concealed from the public that its asbestos-contaminated talc was poisoning women for generations. It used its powerful marketing arm to target Black women and other minorities, bullied the FDA to look the other way, and is now attempting to abuse the bankruptcy system to avoid its responsibility."

The strategy is known in legal circles as the "Texas Two-Step" because Texas law allows economically viable companies to incorporate in the state and then transfer liabilities to another entity with limited or no assets. In a recent similar case, In re DBMP LLC , U.S. Bankruptcy Judge J. Craig Whitley was critical of the practice and said personal injury claimants may have been defrauded in the process. In recent years, other companies including Georgia-Pacific LLC also split off asbestos liabilities through divisional mergers before placing them in bankruptcy.

"J&J has not denied they are considering such an outrageous plan," says Michelle Parfitt , co-lead counsel in the Talcum Powder MDL and Senior Partner at Ashcraft and Gerel , who also represents the plaintiffs. "If J&J is willing to resolve these claims within the civil court system, then such an injunction would have no effect on J&J's business operations and should not create any objections on their part."

Birchfield says the filing could have been made in several other states, but Missouri was chosen because several talc-related trials are pending there. The next trial is scheduled to begin September 7 , in St. Louis .

"This scheme is part of a disturbing trend," says Alexandra Walsh , founder of Walsh Law .  "If J&J is allowed to evade its obligations in this way, it will set a dangerous precedent, prompting other hugely profitable corporations to use the bankruptcy laws to shirk responsibility for their wrongdoing."

Dozens of peer-reviewed medical studies published in the last 35 years have found a statistically significant correlation between talcum powder use and ovarian cancer. Further research has confirmed that talc particles, when applied to the perineal area, can migrate to the ovaries and result in inflammation and related malignancies. In December 2018 , Reuters reported that J&J knew for decades that its talc products were laced with asbestos but kept that information from regulators and the public.

In May 2020 , Johnson & Johnson announced the company would no longer make or market talc-based powders for the North American market.

In June, the U.S. Supreme Court declined to hear an appeal resulting from a $2.1 billion judgment against the company entered by the Missouri Court of Appeals and upheld by the Missouri Supreme Court. That appellate court found that J&J had engaged in "reprehensible conduct" for decades by repeatedly denying the presence of asbestos and the known association between talc use and ovarian cancer.

Media Contact:

Mike Androvett
214-507-5456
mike@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/ovarian-cancer-victims-ask-court-to-block-johnson--johnsons-texas-two-step-bankruptcy-plan-301362146.html

SOURCE Beasley Allen

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Americans favor quality over quantity in pursuit of longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×